2019 Edogawa NICHE Prize Awarded to Dr. Steven Rosenberg for His Pioneering Feat in Tackling Cancer with Immunotherapy
15.8.2019 09:00:00 EEST | Business Wire | Press release
The Edogawa NICHE Committee today announced that the 2019-Edogawa NICHE Prize (www.edogawanicheprize.org) has been awarded to Dr. Steven A. Rosenberg, for his pioneering work in developing effective adoptive immunotherapies and genetically modified T cells which has heralded the birth of a new chapter in the fight against cancer. Dr. Rosenberg’s accomplishment has significantly contributed to the development of several immune system-based drugs and clinically effective immunotherapies including the CAR-T cell therapy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190814005237/en/
Dr. Steven A. Rosenberg, 2019 Edogawa NICHE Prize Awardee (Photo: Business Wire)
Dr. Rosenberg is an epitome of significance of inter-disciplinary interaction in developing clinical solutions, who after his Medical degree at Johns Hopkins University, obtained doctorate in Biophysics. Now leads a strong interdisciplinary team devoted to find novel solutions to cancer, as the Chief, Surgery Branch at the National Cancer Institute (NCI), MD, USA and as Professor of Surgery at the Uniformed Services University of Health Sciences and the George Washington University School of Medicine and Health Science.
Instead of two or more specialists’ interaction, making the inter-disciplinary interaction meaningful, we found one passionate scholar in Dr. Rosenberg, walking through the portals of different domains of science by himself, opening a new path to solve an age-old problem is considered worth that this award be bestowed on him, said Dr. Masahiro Katoh, Chairperson, Edogawa NICHE Committee.
In the 2019 Edogawa NICHE Prize Award ceremony at University of Toronto, Canada, Prof Gary Levy, Chair, Awards Committee & Founding Director, CIHR, Transplant program, will honour Dr. Rosenberg with a medal & plaque, whose acceptance speech will be videocasted in NCRM NICHE 2019 in Tokyo, Japan, followed by 2019 Joyce & James Till Travel Grant recipient, PV Sudharsan, a 2012-FCQ elite sharing how FCQ helped in his career (www.j2t2grant.org), and a presentation on Training Program in Regenerative Medicine (www.regenmedcanada.com).
Instituted in 2018, by Jinseisha trust, which owns Edogawa Hospital, Tokyo and Nichi-In Centre for Regenerative Medicine (NCRM), the Edogawa NICHE Prize honours scientists or clinicians whose contributions lead to the development of prevention, diagnosis or treatment of any disease, through an inter-disciplinary interaction. Scholars who attain top scores in the Fujio Cup Quiz since 2006, a part of NCRM NICHE, (www.ncrmniche.org) and gain FCQ Elite status, have a priority to nominate the awardees, which is unique to this prize.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190814005237/en/
Contact information
Queries to:
GN Corporation Co. Ltd.
Samuel Jk Abraham
info@gncorporation.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 16:00:00 EEST | Press release
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's core mission has always been to increase access to life-saving treatments. It’s about getting the right information to the right care tea
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 16:00:00 EEST | Press release
Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become operational infrastructure without corresponding security maturity. The report also reveals that AI environments are rapidly becoming more interconnected and business critical. Among organizations adopting AI, 64% now run vector databases, 55
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 16:00:00 EEST | Press release
As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructure to monitor airspace activity. The new 86,350-square-foot facility is a major step in readying supply for multiple, large, global markets. The
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 15:51:00 EEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus ® (ocrelizumab) for Multiple Sclerosis9.7.2026 15:45:00 EEST | Press release
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260709701277/en/ “This agreement reflects our focus on pushing high-quality biologics to the finish line efficiently and at scale,” said Anjan Selz, Chief Executive Officer of Polpharma Biologics International AG. “Teva brings reach, discipline and real commercial strength to our strategic collaboration. Combining its global footprint with our technical and develo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom